Clinical trials: Neoadjuvant Immunotherapy
Non-small Cell Lung Cancer (NSCLC)
Neoadjuvant Anti PD-1 Immunotherapy in Resectable Non-small Cell Lung Cancer
NEOMUN is designed as an open-label, single arm, prospective, monocenter, phase II study of pembrolizumab in a neoadjuvant setting in patients with non-small cell lung cancer of Stage II/IIIA suitable for curative intent surgery.
- Trial name
- NEOMUN (NCT03197467)
- Testing
- Pembrolizumab
- Where
- Germany
- Volunteers
- 30 people
- Sponsor
- AIO-Studien-gGmbH
Non-surgical Management;dMMR/MSI-H Gastric Cancer;Neoadjuvant Immunotherapy
Non-surgical Management After NIT for dMMR/MSI-H GC
Gastric cancer is one of the most common cancers worldwide and has a poor prognosis Immunotherapy significantly improves the prognosis of gastric cancer.
- Trial name
- NCT07646574
- Where
- China
- Volunteers
- 12 people
- Sponsor
- Yong Zhou
Breast Cancer
HER-2 Pulsed DC Vaccine to Prevent Recurrence of Invasive Breast Cancer Post Neoadjuvant Chemotherapy
The primary goals of this trial will be to determine the safety and immune activity of HER-2 pulsed DC1 vaccine in patients with high risk HER-2pos breast cancer with residual disease post neoadjuvant therapy.
- Trial name
- Neoadjuvant (NCT02061423)
- Testing
- HER-2 pulsed Dendritic Cell Vaccine
- Where
- 2 sites in United States
- Volunteers
- 7 people
- Sponsor
- H. Lee Moffitt Cancer Center and Research Institute
Female, Age ≥ 18 Years Old, No Previous Systemic Treatment for the Current Disease, Including Surgery, Antitumor Radiochemotherapy/Immunotherapy
Neoadjuvant Chemotherapy Plus Cadonilimab for Locally Advanced Cervical Cancer
Main Purpose of this study is to determine the efficacy and safety of Cadonilimab combined with chemotherapy (cisplatin) for locally advanced cervical cancer.
- Conditions
- Female, Age ≥ 18 Years Old, No Previous Systemic Treatment for the Current Disease, Including Surgery, Antitumor Radiochemotherapy/Immunotherapy, ECOG Score of 0-1, Histologically Confirmed Cervical Cancer, FIGO Stage IB3, IIA2, IIB, IIIC, and Assessed by the Researcher as Resectable Lesion
- Trial name
- NCT07104149
- Testing
- Cadonilimab combined with cisplatin
- Where
- China
- Volunteers
- 29 people
- Sponsor
- The First Affiliated Hospital of Zhengzhou University
HR+/HER2- Breast Cancer
Combined Chemo-immunotherapy Plus SBRT in Neoadjuvant Treatment for Luminal Subtype Breast Cancer
This study is a prospective, randomized controlled clinical trial designed to evaluate the efficacy and safety of combining radiotherapy, chemotherapy, and immunotherapy in the neoadjuvant treatment of high-risk HR+/HER2- breast…
- Trial name
- CISN-L (NCT07254858)
- Testing
- Neoadjuvant radiotherapy, Neoadjuvant Chemotherapy (NACT), Immunotherapy (Sintilimab)
- Where
- China
- Volunteers
- 302 people
- Sponsor
- First Affiliated Hospital of Wenzhou Medical University